BRIEF published on 09/06/2024 at 17:50, 7 months 6 days ago Modification of the rights attached to the categories of shares of Median Technologies Voting Rights Capital Actions Median Technologies Modification Of Rights
PRESS RELEASE published on 09/06/2024 at 17:45, 7 months 6 days ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and shares as of August 31, 2024, in accordance with regulatory requirements. Company uses AI for cancer diagnoses and treatments globally Voting Rights Shares AI Median Technologies Cancer Diagnosis
BRIEF published on 09/04/2024 at 17:50, 7 months 8 days ago Median Technologies: Promising results for the diagnosis of lung cancer Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS Pivotal Study
PRESS RELEASE published on 09/04/2024 at 17:45, 7 months 8 days ago Inside Information / Other news releases Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software at IASLC 2024 World Conference on Lung Cancer. eyonis™ LCS achieves high accuracy in detecting lung cancer Median Technologies Lung Cancer Eyonis LCS IASLC 2024 Diagnostic Software
BRIEF published on 08/29/2024 at 17:50, 7 months 14 days ago Median Technologies: eyonis achieves REALITY study objectives Screening Median Technologies Lung Cancer Eyonis™ LCS AUC
BRIEF published on 07/18/2024 at 18:01, 8 months 25 days ago Median Technologies unveils half-year results and strategic advances Artificial Intelligence Turnover Backlog ICRO Eyonis™ LCS
PRESS RELEASE published on 07/18/2024 at 17:56, 8 months 25 days ago Inside Information / News release on accounts, results Median Technologies reports record iCRO backlog and eyonis™ LCS on-track for pivotal study readout in August. Revenue at €10.9 million, cash at €16 million. CEO to provide update via webcast on July 24, 2024 Revenue Growth Median Technologies ICRO Eyonis LCS Pivotal Study
BRIEF published on 06/07/2024 at 17:50, 10 months 5 days ago Changes in Shareholder Voting Rights at Median Technologies Share Capital Voting Rights French Regulations Median Technologies Non-voting Shares
PRESS RELEASE published on 06/07/2024 at 17:45, 10 months 5 days ago Changes in the rights attaching to the classes of shares or securities Median Technologies discloses total voting rights and share capital as of May 31, 2024, in compliance with French regulations. The company specializes in AI-driven solutions for cancer diagnosis and treatment Share Capital Voting Rights AI Solutions Median Technologies Cancer Diagnosis
BRIEF published on 05/29/2024 at 17:50, 10 months 14 days ago Median Technologies to Attend 2024 ASCO Annual Meeting in Chicago Clinical Trials Oncology Imaging Solutions Median Technologies ASCO Annual Meeting
Published on 04/12/2025 at 15:45, 1 day ago New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice Presid
Published on 04/12/2025 at 02:00, 1 day 14 hours ago Battery X Metals Announces Provisional Patent Application with United States Patent & Trademark Office for Lithium-Ion Battery Rebalancing Technology Innovations
Published on 04/12/2025 at 00:10, 1 day 16 hours ago Applied Minerals, Inc. Files Motion to Approve Disclosure Statement
Published on 04/11/2025 at 23:45, 1 day 16 hours ago Gold Terra Closes First Tranche of Financing Package with Support from Osisko Gold Royalties
Published on 04/11/2025 at 21:45, 1 day 18 hours ago OPPO Unveils Agentic AI Initiative at Google Cloud Next 2025, Showcasing Innovations and Leadership in AI Experiences
Published on 04/11/2025 at 18:38, 1 day 21 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/11/2025 at 18:23, 1 day 22 hours ago EQS-Adhoc: Cherry SE: Cherry SE recognizes asset impairment for 2024; updates adjusted EBITDA margin for fiscal year 2024
Published on 04/11/2025 at 18:30, 1 day 22 hours ago Reclassification of shares within the Feuillet family concert with no impact on the control of the company
Published on 04/11/2025 at 18:00, 1 day 22 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/03/2025
Published on 04/11/2025 at 17:45, 1 day 22 hours ago NFL Biosciences presents its 2024 annual results and provides an update on its clinical program
Published on 04/11/2025 at 13:49, 2 days 2 hours ago Statement about the number of shares composing the share capital and the number of voting rights as at March 31, 2025
Published on 04/11/2025 at 13:36, 2 days 2 hours ago Number of shares and voting rights - March 2025 (In French only)
